Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 33, 2022 - Issue 4
Submit an article Journal homepage
146
Views
1
CrossRef citations to date
0
Altmetric
Articles

Assessment of topical steroid phobia in dermatology patients, a cross-sectional study from an urban area of Pakistan

Sadia MasoodDepartment of Medicine, Aga Khan University Hospital Karachi, Karachi, PakistanCorrespondence[email protected]
,
Palwasha JalilDepartment of Medicine, Aga Khan University Hospital Karachi, Karachi, Pakistan
,
Safia AwanDepartment of Medicine, Aga Khan University Hospital Karachi, Karachi, Pakistan
,
Unzela GhulamDepartment of Medicine, Aga Khan University Hospital Karachi, Karachi, Pakistan
&
Sabeika Raza KerawalaDepartment of Medicine, Aga Khan University Hospital Karachi, Karachi, Pakistan
Pages 2331-2334 | Received 27 Jun 2021, Accepted 19 Jul 2021, Published online: 01 Aug 2021

Reference

  • Kragballe K. Topical corticosteroids: mechanisms of action. Acta Derm Venereol Suppl (Stockh)). 1989;151:7.
  • Gupta LK, Martin AM, Agarwal N, et al. Guidelines for the management of Stevens–Johnson syndrome/toxic epidermal necrolysis: An Indian perspective. Indian J Dermatol Venereol Leprol. 2016;82(6):603–625.
  • Coondoo A, Phiske M, Verma S, et al. Side-effects of topical steroids: A long overdue revisit. Indian Dermatol Online J. 2014;5(4):416–425.
  • Hengge UR, Ruzicka T, Schwartz RA, et al. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54(1):1–15.
  • Raffin D, Giraudeau B, Samimi M, et al. Corticosteroid phobia among pharmacists regarding atopic dermatitis in children: a national French survey. Acta Derm Venereol. 2016;96(2):177–180.
  • Kojima R, Fujiwara T, Matsuda A, et al. Factors associated with steroid phobia in caregivers of children with atopic dermatitis. Pediatr Dermatol. 2013;30(1):29–35.
  • Li AW, Yin ES, Antaya RJ. Topical corticosteroid phobia in atopic dermatitis: a systematic review. JAMA Dermatol. 2017;153(10):1036–1042.
  • Fisher DA. Adverse effects of topical corticosteroid use. Western Journal of Medicine. 1995;162(2):123.
  • Moret L, Anthoine E, Aubert-Wastiaux H, et al. TOPICOP©: a new scale evaluating topical corticosteroid phobia among atopic dermatitis outpatients and their parents. PLoS One. 2013;8(10):e76493.
  • Gonzales F, Ramdane N, Delebarre‐Sauvage C, et al. Monitoring of topical corticosteroid phobia in a population of parents with children with atopic dermatitis using the TOPICOP® scale: prevalence, risk factors and the impact of therapeutic patient education. J Eur Acad Dermatol Venereol. 2017;31(3):e172–e174.
  • Song SY, Jung S-Y, Kim E. Steroid phobia among general users of topical steroids: a cross-sectional nationwide survey. J Dermatolog Treat. 2019;30(3):245–250.
  • Stalder JF, Aubert H, Anthoine E, et al. Topical corticosteroid phobia in atopic dermatitis: International feasibility study of the TOPICOP score. Allergy. 2017;72(11):1713–1719.
  • Charman C, Morris A, Williams H. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol. 2000;142(5):931–936.
  • Aubert‐Wastiaux H, Moret L, Le Rhun A, et al. Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency. Br J Dermatol. 2011;165(4):808–814.
  • Fukaya M, Sato K, Sato M, et al. Topical steroid addiction in atopic dermatitis. Drug Healthc Patient Saf. 2014;6(131):131–138.
  • Hon KLE, Kam WYC, Leung TF, et al. Steroid fears in children with eczema. Acta Paediatr. 2006;95(11):1451–1455.
  • Fischer G. Compliance problems in paediatric atopic eczema. Australas J Dermatol. 1996;37 Suppl 1:S10–S13.
  • Müller SM, Tomaschett D, Euler S, et al. Topical corticosteroid concerns in dermatological outpatients: a cross-sectional and interventional study. Dermatology. 2016;232(4):444–452.
  • Choi E, Chandran NS, Tan C. Corticosteroid phobia: a questionnaire study using TOPICOP score. Singapore Med J. 2020;61(3):149–153.
  • Contento M, Cline A, Russo M. Steroid Phobia: A review of prevalence, risk factors, and interventions. Am J Clin Dermatol. 2021:1–5.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.